NICE backs five new treatments, including Novartis' Zykadia, Mekinist
NICE最近同意了5个新方案进入医保，如诺华的色瑞替尼、 曲美替尼联合达拉非尼治疗恶黑。色瑞替尼30天费用为4923-pound ($7220) ，曲美替尼联合达拉非尼方案28天费用为10 080 pounds ($14 776) 。而本月初NICE因为费用收益的情况，也拒绝了Vertex的 囊性纤维化药物Orkambi (lumacaftor/ivacaftor)和罗氏的Cotellic (cobimetinib) 联合Zelboraf (vemurafenib) 方案。
医保是所有国家都头疼的事，中国前段时间也和三个药厂进行医保价格谈判，最后大家平均降价50%以上，而进入医保目录。
医保机构都会根据费用的情况，来决定药物是否进入医保，可人的生命如何用价格衡量。如Orkambi没进医保，就引起患者的抗议。
原文如下：
NICE backs five new treatments, including Novartis' Zykadia, Mekinist
(Ref: NICE, The Telegraph)
June 22nd, 2016
By: Joe Barber
The National Institute for Health and Care Excellence on Wednesday recommended NHS reimbursement of five new treatments, including drugs for lung cancer, melanoma, high cholesterol and hidradenitis. The therapies approved for funding by the agency include Novartis' non-small-cell lung cancer (NSCLC) treatment Zykadia (ceritinib), as well as the company's Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for use in certain patients with melanoma. NICE noted that the Swiss drugmaker agreed to discounts on the list prices of the drugs for both indications.
Zykadia was authorised by European regulators in May last year for the treatment of adults with ALK-positive advanced NSCLC. NICE previously declined to approve reimbursement for the drug, but subsequently relented after Novartis agreed to an undisclosed discount on its 4923-pound ($7220) price for a 30-day supply. "The Department of Health considered that this patient access scheme would not constitute an excessive administrative burden on the NHS," NICE commented.
Meanwhile, the combination of Mekinist and Tafinlar was cleared in Europe in September 2015 for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation. The combination regimen is normally priced at 10 080 pounds ($14 776) for a 28-day supply.
Additionally, other therapies approved for coverage by NICE included Amgen's cholesterol drug Repatha (evolocumab), Sanofi and Regeneron Pharmaceuticals' cholesterol treatment Praluent (alirocumab) and AbbVie's Humira (adalimumab) for the treatment of patients with hidradenitis.
Earlier this month, NICE backed reimbursement for the combination of Bristol-Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab) for use in patients with melanoma. Conversely, the agency declined to recommend Vertex Pharmaceuticals' cystic fibrosis treatment Orkambi (lumacaftor/ivacaftor), due to cost, while the agency rejected Roche's Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) for the treatment of certain adults with unresectable or metastatic melanoma on the grounds of cost-effectiveness.
